EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, MYGN: Myriad Genetics Inc

31 Dec 25 15:59
LAST:

6.150

CHANGE:
 0.02		OPEN:
6.100		HIGH:
6.195		ASK:
28.150		VOLUME:
306.0K
CHG(%):
0.32		PREV:
6.170		LOW:
6.100		BID:
29.290		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
31 Dec 256.1406.1956.1006.150703.9K
30 Dec 256.3006.3006.1506.170484.7K
29 Dec 256.5706.5706.2906.310663.3K
26 Dec 256.5306.6206.3906.480936.4K
24 Dec 256.5106.5606.3806.550424.7K
23 Dec 256.7306.7706.5356.560498.7K
22 Dec 256.5806.8906.5106.7601.0M
19 Dec 256.7006.7406.5306.5503.26M
18 Dec 257.0307.2006.6156.700759.6K
17 Dec 256.9207.1256.8006.950691.8K

PROFILE

Name:Myriad Genetics Inc
About:Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company has a strategic alliance with SOPHiA GENETICS SA for the development of liquid biopsy companion diagnostic (CDx) test. The co
Sector:Healthcare
Address:322 North 2200 West, Salt Lake City, UT, United States, 84116
Website:https://www.myriad.com
CUSIP:62855J104
CIK:0000899923
ISIN:US62855J1043
FIGI:BBG000D9H9F1
LEI:52990044IHUOUMETT163

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-5.80 
Forward P/E:53.60 
PEG Ratio:-0.01 
Price to Sales:0.90 
Price to Book:1.93 
Profit Margin:-0.47 
Operating Margin:-0.06 
Return on Assets:-0.05 
Return on Equity:-0.70 
EPS Ratio:-4.31 
Revenue:832.9M 
Shares:93.04M 
Market Cap:572.22M 

TECHNICAL INDICATORS

MA5:6.333.0%
MA10:6.526.0%
MA20:6.8511.3%
MA50:7.1015.4%
MA100:7.0614.8%
MA200:6.485.3%
RSI14:19.66 
WPR14:-100.00 
MTM14:-1.15
ROC14:-0.16 
ATR:0.27 
Week High:6.627.6%
Week Low:6.100.8%
Month High:7.5422.6%
Month Low:6.105.3%
Year High:15.47151.5%
Year Low:3.7663.6%
Volatility:41.65 

RECENT SPLITS

Date Ratio
26 Mar 20092-1
12 Sep 20002-1

RECENT DIVIDENDS

Date Amount
01 Jul 2009$1.75
15 Jun 2009$1.75